New Insulin Delivery Recommendations

Mayo Clinic Proceedings

Volumn 91, Issue 9, 2016, Pages 1231-1255

  Frid, Anders H ^a   Kreugel, Gillian ^b   Grassi, Giorgio ^c   Halimi, Serge ^d   Hicks, Debbie ^e   Hirsch, Laurence J ^f   Smith, Mike J ^g   Wellhoener, Regine ^h   Bode, Bruce W ⁱ   Hirsch, Irl B ^j   Kalra, Sanjay ^k   Ji, Linong ^l   Strauss, Kenneth W ^m  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

^e BARNET ENFIELD AND HARINGEY MENTAL HEALTH NHS TRUST   (United Kingdom)

^f BD Technologies   (United States)

^g BD Medical   (United States)

^h Private practice   (Germany)

ⁱ ATLANTA DIABETES ASSOCIATES   (United States)

^j UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^k Bharti Hospital & BRIDE ^*  (India)

^l PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^m BD Diabetes Care   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HUMAN INSULIN; INSULIN; INSULIN DERIVATIVE; ISOPHANE INSULIN; LONG ACTING INSULIN; ANTIDIABETIC AGENT;

CLINICAL PRACTICE; DIABETES MELLITUS; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; GENERAL PRACTITIONER; HEALTH CARE COST; HUMAN; HYPOGLYCEMIA; INFECTION RISK; INFUSION THERAPY; INJECTION; ITALY; LIPOHYPERTROPHY; LONG TERM CARE; MEDICAL EXPERT; NEEDLE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; REVIEW; SHARPS DISPOSAL; WORKSHOP; DIABETES MELLITUS, TYPE 2; FEMALE; MALE; STANDARDS;

DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS; INSULIN; ITALY; MALE; PRACTICE GUIDELINES AS TOPIC;

EID: 84990982216     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2016.06.010     Document Type: Review

References (285)

1. 1 Frid, A., Hirsch, L., Gaspar, R., et al. New injection recommendations for patients with diabetes. Diabetes Metab 36:suppl 2 (2010), S3–S18.
2. 2 Fitter4Diabetes website. http://www.fitter4diabetes.com. Accessed June 7, 2016.
3. 3 Strauss, K., Insulin injection techniques: report from the 1st International Insulin Injection Technique Workshop, Strasbourg, France—June 1997. Pract Diabetes Int 15:6 (1998), 16–20.
4. 4 Strauss, K., De Gols, H., Letondeur, C., Matyjaszczyk, M., Frid, A., The second injection technique event (SITE), May 2000, Barcelona, Spain. Pract Diabetes Int 19:1 (2002), 17–21.
5. 5 Costigliola, V., Frid, A., Letondeur, C., Strauss, K., Needlestick injuries in European nurses in diabetes. Diabetes Metab 38:suppl 1 (2012), S9–S14.
6. 6 Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 (See especially chapter 8, Assessing Risk of Bias in Included Studies). http://handbook.cochrane.org. Accessed June 9, 2016.
7. 7 Guyatt, G., Gutterman, D., Baumann, M.H., et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest 129:1 (2006), 174–181.
8. 8 Gibney, M., Arce, C., Byron, K., Hirsch, L., Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations. Curr Med Res Opin 26:6 (2010), 1519–1530.
9. 9 Lo Presti, D., Ingegnosi, C., Strauss, K., Skin and subcutaneous thickness at injecting sites in children with diabetes: ultrasound findings and recommendations for giving injection. Pediatr Diabetes 13:7 (2012), 525–533.
10. 10 Marran, K., Segal, D., SKINNY—Skin thickness and Needles in the Young. S Afr J CH 8:3 (2014), 92–95.
11. 11 Wang W, Guo X, Shen G, et al. Skin and subcutaneous thickness at insulin injection sites in Chinese patients with diabetes: clinical implications [published June 8, 2016]. Diabetes Metab. http://dx.doi.org/10.1016/j.diabet.2016.04.010.
12. 12 Jain, S.M., Pandey, K., Lahoti, A., Rao, P.K., Evaluation of skin and subcutaneous tissue thickness at insulin injection sites in Indian, insulin naïve, type-2 diabetic adult population. Indian J Endocrinol Metab 17:5 (2013), 864–870.
13. 13 Catambing, I., Villa, M., Ultrasonographic measurement of skin and subcutaneous thickness at insulin injection sites among adult Filipinos with diabetes. J ASEAN Fed Endocr Soc 29:1 (2014), 24–32.
14. 14 Sim, K.H., Hwang, M.S., Kim, S.Y., Lee, H.M., Chang, J.Y., Lee, M.K., The appropriateness of the length of insulin needles based on determination of skin and subcutaneous fat thickness in the abdomen and upper arm in patients with type 2 diabetes. Diabetes Metab J 38:2 (2014), 120–133.
15. 15 Hirsch, L., Byron, K., Gibney, M., Intramuscular risk at insulin injection sites: measurement of the distance from skin to muscle and rationale for shorter-length needles for subcutaneous insulin therapy. Diabetes Technol Ther 16:12 (2014), 867–873.
16. 16 Ludescher, B., Rommel, M., Willmer, T., Fritsche, A., Schick, F., Machann, J., Subcutaneous adipose tissue thickness in adults: correlation with BMI and recommendations for pen needle lengths for subcutaneous self-injection. Clin Endocrinol (Oxf) 75:6 (2011), 786–790.
17. 17 Karges, B., Boehm, B.O., Karges, W., Early hypoglycaemia after accidental intramuscular injection of insulin glargine. Diabet Med 22:10 (2005), 1444–1445.
18. 18 Frid, A., Gunnarson, R., Guntner, P., Linde, P., Effects of accidental intramuscular injection on insulin absorption in IDDM. Diabetes Care 11:1 (1988), 41–45.
19. 19 Spraul, M., Chantelau, E., Koumoulidou, J., Berger, M., Subcutaneous or nonsubcutaneous injection of insulin. Diabetes Care 11:9 (1988), 733–736.
20. 20 Kalra, S., Yashdeep, Y., Clinical applications of intramuscular insulin. J Endocrinol Metab 4:3 (2014), 40–43.
21. 21 Sindelka, G., Heinemann, L., Berger, M., Frenck, W., Chantelau, E., Effect of insulin concentration, subcutaneous fat thickness and skin temperature on subcutaneous insulin absorption in healthy subjects. Diabetologia 37:4 (1994), 377–380.
22. 22 Becker, D., Individualized insulin therapy in children and adolescents with type 1 diabetes. Acta Paediatr 87:suppl 425 (1998), S20–S24.
23. 23 Uzun, S., lnanc, N., Azal, S., Determining optimal needle length for subcutaneous insulin injection. J Diabetes Nurs 5:10 (2001), 83–87.
24. 24 Hirsch, L., Klaff, L., Bailey, T., et al. Comparative glycemic control, safety and patient ratings for a new 4 mm × 32G insulin pen needle in adults with diabetes. Curr Med Res Opin 26:6 (2010), 1531–1541.
25. 25 Miwa, T., Itoh, R., Kobayashi, T., et al. Comparison of the effects of a new 32-gauge × 4-mm pen needle and a 32-gauge × 6-mm pen needle on glycemic control, safety, and patient ratings in Japanese adults with diabetes. Diabetes Technol Ther 14:12 (2012), 1084–1090.
26. 26 Nagai, Y., Ohshige, T., Arai, K., Kobayashi, H., Sada, Y., Ohmori, S., Comparison between shorter straight and thinner microtapered insulin injection needles. Diabetes Technol Ther 15:7 (2013), 550–555.
27. 27 Hirose, T., Ogihara, T., Tozaka, S., Kanderian, S., Watada, H., Identification and comparison of insulin pharmacokinetics injected with a new 4-mm needle vs 6- and 8-mm needles accounting for endogenous insulin and C-peptide secretion kinetics in non-diabetic adult males. J Diabetes Investig 4:3 (2013), 287–296.
28. 28 Bergenstal, R.M., Strock, E.S., Peremislov, D., et al. Safety and efficacy of insulin therapy delivered via a 4mm pen needle in obese patients with diabetes. Mayo Clin Proc 90:3 (2015), 329–338.
29. 29 Kreugel, G., Keers, J.C., Jongbloed, A., Verweij-Gjaltema, A.H., Wolffenbuttel, B.H.R., The influence of needle length on glycemic control and patient preference in obese diabetic patients. Diabetes, 58, 2009, A117.
30. 30 Hirsch, L., Klaff, L., Bailey, T., et al. Comparative glycemic control, safety and patient ratings for a new 4 mm × 32G insulin pen needle in adults with diabetes. Curr Med Res Opin 26:6 (2010), 1531–1541.
31. 31 Schwartz, S., Hassman, D., Shelmet, J., et al. A multicenter, open-label, randomized, two-period crossover trial comparing glycemic control, satisfaction, and preference achieved with a 31 gauge x 6mm needle versus a 29 gauge x 12.7mm needle in obese patients with diabetes mellitus. Clin Ther 26:10 (2004), 1663–1678.
32. 32 Ross, S.A., Jamal, R., Leiter, L.A., et al. Evaluation of 8 mm insulin pen needles in people with type 1 and type 2 diabetes. Pract Diabetes Int 16:5 (1999), 145–148.
33. 33 Tubiana-Rufi, N., Belarbi, N., Du Pasquier-Fediaevsky, L., et al. Short needles (8 mm) reduce the risk of intramuscular injections in children with type 1 diabetes. Diabetes Care 22:10 (1999), 1621–1625.
34. 34 Strauss, K., Hannet, I., McGonigle, J., et al. Ultra-short (5mm) insulin needles: trial results and clinical recommendations. Pract Diabetes Int 16:7 (1999), 218–221.
35. 35 Kreugel, G., Keers, J.C., Kerstens, M.N., Wolffenbuttel, B.H., Randomized trial on the influence of the length of two insulin pen needles on glycemic control and patient preference in obese patients with diabetes. Diabetes Technol Ther 13:7 (2011), 737–741.
36. 36 Iwanaga, M., Kamoi, K., Patient perceptions of injection pain and anxiety: a comparison of NovoFine 32-gauge tip 6 mm and Micro Fine Plus 31-gauge 5 mm needles. Diabetes Technol Ther 11:2 (2009), 81–86.
37. 37 McKay, M., Compion, G., Lytzen, L., A comparison of insulin injection needles on patients' perceptions of pain, handling, and acceptability: a randomized, open-label, crossover study in subjects with diabetes. Diabetes Technol Ther 11:3 (2009), 195–201.
38. 38 Frid, A., Linde, B., Intraregional differences in absorption of unmodified insulin from the abdominal wall. Diabet Med 9:3 (1992), 236–239.
39. 39 de la Peña, A., Yeo, K.P., Linnebjerg, H., et al. Subcutaneous injection depth does not affect the pharmacokinetics or glucodynamics of insulin lispro in normal weight or healthy obese subjects. J Diabetes Sci Technol 9:4 (2015), 824–830.
40. 40 Birkebaek, N.H., Solvig, J., Hansen, B., Jorgensen, C., Smedegaard, J., Christiansen, J.S., A 4-mm needle reduces the risk of intramuscular injections without increasing backflow to skin surface in lean diabetic children and adults. Diabetes Care, 31(9), 2008, e65.
41. 41 Hofman, P.L., Derraik, J.G., Pinto, T.E., et al. Defining the ideal injection techniques when using 5-mm needles in children and adults. Diabetes Care 33:9 (2010), 1940–1944.
42. 42 Hofman, P.L., Lawton, S.A., Peart, J.M., et al. An angled insertion technique using 6-mm needles markedly reduces the risk of intramuscular injections in children and adolescents. Diabet Med 24:12 (2007), 1400–1405.
43. 43 Jamal, R., Ross, S.A., Parkes, J.L., Pardo, S., Ginsberg, B.H., Role of injection technique in use of insulin pens: prospective evaluation of a 31-gauge, 8mm insulin pen needle. Endocr Pract 5:5 (1999), 245–250.
44. 44 Kreugel, G., Beijer, H.J.M., Kerstens, M.N., ter Maaten, J.C., Sluiter, W.J., Boot, B.S., Influence of needle size for SC insulin administration on metabolic control and patient acceptance. Eur Diabetes Nurs 4:2 (2007), 1–5.
45. 45 Van Doorn, L.G., Alberda, A., Lytzen, L., Insulin leakage and pain perception with NovoFine 6 mm and NovoFine 12 mm needle lengths in patients with type 1 or type 2 diabetes. Diabet Med, 1, 1998, S50.
46. 46 How do I decide where to inject? Joslin Diabetes Center website. http://www.joslin.org/info/how_to_improve_the_insulin_injection_experience.html. Accessed June 8, 2016.
47. 47 Strauss, K., Insulin injection techniques. Pract Diabetes Int 15 (1998), 181–184.
48. 48 Thow, J.C., Coulthard, A., Home, P.D., Insulin injection site tissue depths and localization of a simulated insulin bolus using a novel air contrast ultrasonographic technique in insulin treated diabetic subjects. Diabet Med 9:10 (1992), 915–920.
49. 49 Thow, J.C., Home, P.D., Insulin injection technique: depth of injection is important. BMJ 301:6742 (1990), 3–4.
50. 50 Hildebrandt, P., Skinfold thickness, local subcutaneous blood flow and insulin absorption in diabetic patients. Acta Physiol Scand Suppl 603 (1991), 41–45.
51. 51 Vora, J.P., Peters, J.R., Burch, A., Owens, D.R., Relationship between absorption of radiolabeled soluble insulin subcutaneous blood flow, and anthropometry. Diabetes Care 15:11 (1992), 1484–1493.
52. 52 Laurent, A., Mistretta, F., Bottigioli, D., et al. Echographic measurement of skin thickness in adults by high frequency ultrasound to assess the appropriate microneedle length for intradermal delivery of vaccines. Vaccine 25:34 (2007), 6423–6430.
53. 53 Lasagni, C., Seidenari, S., Echographic assessment of age-dependent variations of skin thickness: a study on 162 subjects. Skin Res Technol 1:2 (1995), 81–85.
54. 54 Swindle, L.D., Thomas, S.G., Freeman, M., Delaney, P.M., View of normal human skin in vivo as observed using fluorescent fiber-optic confocal microscopic imaging. J Invest Dermatol 121:4 (2003), 706–712.
55. 55 Huzaira, M., Rius, F., Rajadhyaksha, M., Anderson, R.R., González, S., Topographic variations in normal skin, as viewed by in vivo reflectance confocal microscopy. J Invest Dermatol 116:6 (2001), 846–852.
56. 56 Tan, C.Y., Statham, B., Marks, R., Payne, P.A., Skin thickness measured by pulsed ultrasound: its reproducibility, validation and variability. Br J Dermatol 106:6 (1982), 657–667.
57. 57 Solvig J, Christiansen JS, Hansen B, Lytzen L. Localisation of potential insulin deposition in normal weight and obese patients with diabetes using Novofine 6 mm and Novofine 12 mm needles. Paper presented at: 5th Annual Conference of the Federation of European Nurses in Diabetes; September 14-15, 2000; Jerusalem, Israel.
58. 58 Ignuat, D., Fu, H., Comparison of insulin diluent leakage postinjection using two different needle lengths and injection volumes in obese patients with type 1 or type 2 diabetes mellitus. J Diabetes Sci Technol 6:2 (2012), 389–393.
59. 59 Hirsch, L.J., Gibney, M.A., Albanese, J., et al. Comparative glycemic control, safety and patient ratings for a new 4 mm x 32G insulin pen needle in adults with diabetes. Curr Med Res Opin 26:6 (2010), 1531–1541.
60. 60 Hirsch, L.J., Gibney, M.A., Li, L., Bérubé, J., Glycemic control, reported pain and leakage with a 4 mm × 32 G pen needle in obese and non-obese adults with diabetes: a post hoc analysis. Curr Med Res Opin 28:8 (2012), 1305–1311.
61. 61 Polak, M., Beregszaszi, M., Belarbi, N., et al. Subcutaneous or intra-muscular injections of insulin in children: are we injecting where we think we are?. Diabetes Care 19:12 (1996), 1434–1436.
62. 62 Vaag, A., Handberg, A., Lauritzen, M., et al. Variation in absorption of NPH insulin due to intramuscular injection. Diabetes Care 13:1 (1990), 74–76.
63. 63 Thow, J., Johnson, A., Fulcher, G., Home, P., Different absorption of Isophane (NPH) Insulin from subcutaneous and intramuscular sites suggests a need to reassess recommended insulin injection technique. Diabet Med 7:3 (1990), 600–602.
64. 64 Rave, K., Heise, T., Weyer, C., et al. Intramuscular versus subcutaneous injection of soluble and lispro insulins: comparison of metabolic effects in healthy subjects. Diabet Med 15:9 (1998), 747–751.
65. 65 Alexander, H., Dugale, A., Fascial planes with subcutaneous fat in humans. Eur J Clin Nutr 46:12 (1992), 903–906.
66. 66 Gasperoni, C., Salgarello, M., Liposuction related to the anatomy of subcutaneous fat and superficial fascial system. Aesthetic Plast Surg 19:1 (1995), 13–20.
67. 67 Johnson, D., Cormack, G.C., Abrahams, P.H., Dixon, A.K., Computed tomographic observations on subcutaneous fat: implications for liposuction. Plast Reconstr Surg 97:2 (1996), 387–396.
68. 68 Markman, B., Barton, J.F., Anatomy of the subcutaneous tissue of the trunk and lower extremity. Plast Reconstr Surg 80:2 (1987), 248–254.
69. 69 Kelley, D.E., Thaete, F.L., Troost, F., Huwe, T., Goodpaster, B.H., Subdivisions of subcutaneous abdominal adipose tissue and insulin resistance. Am J Physiol Endocrinol Metab 278:5 (2000), E941–E948.
70. 70 de la Peña, A., Ma, X., Reddy, S., Ovalle, F., Bergenstal, R.M., Jackson, J.A., Application of PK/PD modeling and simulation to dosing regimen optimization of high-dose human regular U-500 insulin. J Diabetes Sci Technol 8:4 (2014), 821–829.
71. 71 Hofman, P.L., Lawton, S.A., Peart, J.M., et al. An angled insertion technique using 6mm needles markedly reduces the risk of IM injections in children and adolescents. Diabet Med 24:12 (2007), 1400–1405.
72. 72 Koivisto, V.A., Felig, P., Alterations in insulin absorption and in blood glucose control associated with varying insulin injection sites in diabetic patients. Ann Intern Med 92:1 (1980), 59–61.
73. 73 Annersten, M., Willman, A., Performing subcutaneous injections: a literature review. Worldviews Evid-Based Nurs 2:3 (2005), 122–130.
74. 74 Vidal, M., Colungo, C., Jansà, M., Actualización sobre técnicas y sistemas de administración de la insulina (I). Av Diabetol 24:3 (2008), 175–190.
75. 75 Fleming, D., Jacober, S.J., Vanderberg, M., Fitzgerald, J.T., Grunberger, G., The safety of injecting insulin through clothing. Diabetes Care 20:3 (1997), 244–247.
76. 76 Bantle, J.P., Neal, L., Frankamp, L.M., Effects of the anatomical region used for insulin injections on glycaemia in type 1 diabetes subjects. Diabetes Care 16:12 (1993), 1592–1597.
77. 77 Gorman, K.C., Good hygiene versus alcohol swabs before insulin injections. [letter] Diabetes Care 16:6 (1993), 960–961.
78. 78 Danish Nurses Organization. Evidence-based Clinical Guidelines for Injection of Insulin for Adults with Diabetes Mellitus. 2nd ed., December 2006, Danish Nurses Organization, Copenhagen, Denmark.
79. 79 Association for Diabetes Care Professionals (EADV). Guideline: The Administration of Insulin with the Insulin Pen. September 2008, Association for Diabetes Care Professionals, Utrecht, the Netherlands.
80. 80 McCarthy, J.A., Covarrubias, B., Sink, P., Is the traditional alcohol wipe necessary before an insulin injection? dogma disputed. [letter] Diabetes Care, 16(1), 1993, 402.
81. 81 Swahn Å, Experiences from 94000 insulin injections given without skin swab. [in Dutch] Sv Läkaresällskapets Handlingar Hygiea, 92, 1982, 160.
82. 82 Le Floch, J.P., Herbreteau, C., Lange, F., Perlemuter, L., Biologic material in needles and cartridges after insulin injection with a pen in diabetic patients. Diabetes Care 21:9 (1998), 1502–1504.
83. 83 Schuler, G., Pelz, K., Kerp, L., Is the reuse of needles for insulin injection systems associated with a higher risk of cutaneous complications?. Diabetes Res Clin Pract 16:3 (1992), 209–212.
84. 84 Johansson, U., Amsberg, S., Hannerz, L., et al. Impaired absorption of insulin aspart from lipohypertrophic injection sites. Diabetes Care 28:8 (2005), 2025–2027.
85. 85 Ariza-Andraca, C.R., Altamirano-Bustamante, E., Frati-Munari, A.C., Altamirano-Bustamante, P., Graef-Sanchez, A., Delayed insulin absorption due to subcutaneous edema. Arch Invest Med 22:2 (1991), 229–233.
86. 86 Saez-de Ibarra, L., Gallego, F., Factors related to lipohypertrophy in insulin-treated diabetic patients: role of educational intervention. Pract Diabetes Int 15:1 (1998), 9–11.
87. 87 Young, R.J., Hannan, W.J., Frier, B.M., et al. Diabetic lipohypertrophy delays insulin absorption. Diabetes Care 7:5 (1984), 479–480.
88. 88 Chowdhury, T.A., Escudier, V., Poor glycaemic control caused by insulin induced lipohypertrophy. BMJ 327:7411 (2003), 383–384.
89. 89 Overland, J., Molyneaux, L., Tewari, S., et al. Lipohypertrophy: does it matter in daily life? a study using a continuous glucose monitoring system. Diabetes Obes Metab 11:5 (2009), 460–463.
90. 90 Frid, A., Linden, B., Computed Tomography of Injection Sites in Patients With Diabetes Mellitus: Injection and Absorption of Insulin. [thesis], 1992, Karolinska Institutet, Stockholm, Sweden.
91. 91 Tandon, N., Kalra, S., Balhara, Y.S., et al. Forum for Injection Technique (FIT), India: the Indian recommendations 2.0, for best practice in Insulin Injection Technique, 2015. Indian J Endocr Metab 19:3 (2015), 317–331.
92. 92 Gentile, S., Agrusta, M., Guarino, G., et al. Metabolic consequences of incorrect insulin administration techniques in aging subjects with diabetes. Acta Diabetol 48:2 (2011), 121–125.
93. 93 Asakura, T., A step to prevent blood in the cartridge of an insulin pen. [in Japanese] Progr Med 23:11 (2003), 3066–3071.
94. 94 Asakura, T., Seino, H., Kageyama, M., Yohkoh, N., Technical study of injection force of insulin injectors: at which angle to push the button. [in Japanese] Progr Med 29:2 (2009), 1851–1856.
95. 95 Asakura, T., Comparison of clinically relevant technical attributes of five insulin injection pens. J Diabetes Sci Technol 5:5 (2011), 1203–1209.
96. 96 Bohannon, N.J., Insulin delivery using pen devices: simple-to-use tools may help young and old alike. Postgrad Med 106:5 (1999), 57–58.
97. 97 Dejgaard, A., Murmann, C., Air bubbles in insulin pens. Lancet, 334(8667), 1989, 871.
98. 98 Bärtsch, U., Comtesse, C., Wetekam, B., Insulin pens for treatment of diabetes. [in German] Ther Umsch 63:6 (2006), 398–404.
99. 99 Ginsberg, B.H., Parkes, J.L., Sparacino, C., The kinetics of insulin administration by insulin pens. Horm Metab Res 26:12 (1994), 584–587.
100. 100 Annersten, M., Frid, A., Insulin pens dribble from the tip of the needle after injection. Pract Diabetes Int 17:4 (2000), 109–111.
101. 101 Byetta Pen User Manual, 2007, Eli Lilly & Co, Indianapolis, IN.
102. 102 Chantelau, E., Heinemann, L., Ross, D., Air bubbles in insulin pens. Lancet 334:8659 (1989), 387–388.
103. 103 Maljaars, C., Sharp study needles for single use. [in Dutch] Diabetes Levery 4 (2002), 36–37.
104. 104 Chantelau, E., Lee, D.M., Hemmann, D.M., Zipfel, U., Echterhoff, S., What makes insulin injections painful?. BMJ 303:6793 (1991), 26–27.
105. 105 Torrance, T., An unexpected hazard of insulin injection. Pract Diabetes Int, 19(2), 2002, 63.
106. 106 King, L., Subcutaneous insulin injection technique. Nurs Stand 17:34 (2003), 45–52.
107. 107 Rissler, J., Jørgensen, C., Rye Hansen, M., Hansen, N.A., Evaluation of the injection force dynamics of a modified prefilled insulin pen. Expert Opin Pharmacother 9:13 (2008), 2217–2222.
108. 108 Broadway, C.A., Prevention of insulin leakage after subcutaneous injection. Diabetes Educ, 17(2), 1991, 90.
109. 109 Caffrey, R.M., Diabetes under control: are all syringes created equal?. Am J Nurs 103:6 (2003), 46–49.
110. 110 Ter Braak, E.W., Woodworth, J.R., Bianchi, R., et al. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin. Diabetes Care 19:12 (1996), 1437–1440.
111. 111 Frid, A., Fat thickness and insulin administration: what do we know?. Infusystems Int 5:3 (2006), 17–19.
112. 112 Lippert, W.C., Wall, E.J., Optimal intramuscular needle-penetration depth. Pediatrics 122:3 (2008), e556–e563.
113. 113 Mudaliar, S.R., Lindberg, F.A., Joyce, M., et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 22:9 (1999), 1501–1506.
114. 114 Guerci, B., Sauvanet, J.P., Subcutaneous insulin: pharmacokinetic variability and glycemic variability. Diabetes Metab, 31(4), 2005 4S7-4S24.
115. 115 Owens, D.R., Coates, P.A., Luzio, S.D., Tinbergen, J.P., Kurzhals, R., Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care 23:6 (2000), 813–819.
116. 116 Calara, F., Taylor, K., Han, J., et al. A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4). Clin Ther 27:2 (2005), 210–215.
117. 117 Frid, A., Östman, J., Linde, B., Hypoglycemia risk during exercise after intramuscular injection of insulin in thigh in IDDM. Diabetes Care 13:5 (1990), 473–477.
118. 118 Frid, A., Linden, B., Clinically important differences in insulin absorption from the abdomen in IDDM. Diabetes Res Clin Pract 21:2 (1993), 137–141.
119. 119 Zehrer, C., Hansen, R., Bantle, J., Reducing blood glucose variability by use of abdominal insulin injection sites. Diabetes Educ 16:6 (1985), 474–477.
120. 120 Henriksen, J.E., Djurhuus, M.S., Vaag, A., et al. Impact of injection sites for soluble insulin on glycaemic control in type 1 (insulin-dependent) diabetic patients treated with a multiple insulin injection regimen. Diabetologia 36:8 (1993), 752–758.
121. 121 Henriksen, J.E., Vaag, A., Hansen, I.R., Lauritzen, M., Djurhuus, M.S., Beck-Nielsen, H., Absorption of NPH (isophane) insulin in resting diabetic patients: evidence for subcutaneous injection in the thigh as preferred site. Diabet Med 8:5 (1991), 453–457.
122. 122 Kølendorf, K., Bojsen, J., Deckert, T., Clinical factors influencing the absorption of 125 I-NPH insulin in diabetic patients. Horm Metab Res 15:6 (1983), 274–278.
123. 123 What is the best injection technique? Joslin Diabetes Center website. http://www.joslin.org/info/how_to_improve_the_insulin_injection_experience.html. Accessed June 8, 2016.
124. 124 Jehle, P.M., Micheler, C., Jehle, D.R., Breitig, D., Boehm, B.O., Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens. Lancet 354:9190 (1999), 1604–1607.
125. 125 Brown, A., Steel, J.M., Duncan, C., Duncun, A., McBain, A.M., An assessment of the adequacy of suspension of insulin in pen injectors. Diabet Med 21:6 (2004), 604–608.
126. 126 Nath, C., Mixing insulin: shake, rattle, or roll?. Nursing, 32(5), 2002, 10.
127. 127 Springs, M.H., Shake, rattle, or roll?. Am J Nurs 99:7 (1999), 14–16.
128. 128 Kaiser, P., Maxeiner, S., Weise, A., et al. Assessment of the mixing efficiency of neutral protamine Hagedorn cartridges. J Diabetes Sci Technol 4:3 (2010), 652–657.
129. 129 Kawasaki, E., Asakura, T., Karasawa, H., Yohkoh, N., Examination of the suspensibility of insulin suspensions in clinical use. [in Japanese] J Japan Diabetes Soc 55:10 (2012), 753–760.
130. 130 Ahern, J., Mazur, M.L., Site rotation. Diabetes Forecast 54:4 (2001), 66–68.
131. 131 Perriello, G., Torlone, E., Di Santo, S., et al. Effect of storage temperature on pharmacokinetics and pharmacodynamics of insulin mixtures injected subcutaneously in subjects with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 31:11 (1988), 811–815.
132. 132 Engström L, Jinnerot H, Jonasson E. Thickness of subcutaneous fat tissue where pregnant diabetics inject their insulin: an ultrasound study. Poster presented at: 17th International Diabetes Federation Congress; November 5-10, 2000; Mexico City, Mexico.
133. 133 De Meijer, P.H.E.M., Lutterman, J.A., van Lier, H.J.J., van't Laar, A., The variability of the absorption of subcutaneously injected insulin: effect of injection technique and relation with brittleness. Diabet Med 7:6 (1990), 499–505.
134. 134 Baron, A.D., Kim, D., Weyer, C., Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus. Curr Drug Targets 2:1 (2002), 63–82.
135. 135 Vaag, A., Damgaard Pedersen, K., Lauritzen, M., Hildebrandt, P., Beck-Nielsen, H., Intramuscular versus subcutaneous injection of unmodified insulin: consequences for blood glucose control in patients with type 1 diabetes mellitus. Diabet Med 7:4 (1990), 335–342.
136. 136 Hildebrandt, P., Subcutaneous absorption of insulin in insulin-dependent diabetic patients: influences of species, physico-chemical properties of insulin and physiological factors. Dan Med Bull 38:4 (1991), 337–346.
137. 137 DiMatteo, R.M., DiNicola, D.D., (eds.) Achieving Patient Compliance: The Psychology of Medical Practitioner's Role, 1982, Pergamon Press Inc, New York, NY, 233–256.
138. 138 Joy, S.V., Clinical pearls and strategies to optimize patient outcomes. Diabetes Educ 34:3 (2008), S54–S59.
139. 139 Strauss, K., De Gols, H., Hannet, I., Partanen, T.M., Frid, A., A pan-European epidemiologic study of insulin injection technique in patients with diabetes. Pract Diabetes Int 19:3 (2002), 71–76.
140. 140 Martinez, L., Consoli, S.M., Monnier, L., et al. Studying the Hurdles of Insulin Prescription (SHIP): development, scoring and initial validation of a new self-administered questionnaire. Health Qual Life Outcomes, 5, 2007, 53.
141. 141 Cefalu, W.T., Mathieu, C., Davidson, J., Freemantle, N., Gough, S., Canovatchel, W., Patients' perceptions of subcutaneous insulin in the OPTIMIZE study: a multicenter follow-up study. Diabetes Technol Ther 10:1 (2008), 25–38.
142. 142 Seyoum, B., Abdulkadir, J., Systematic inspection of insulin injection sites for local complications related to incorrect injection technique. Trop Doct 26:4 (1996), 159–161.
143. 143 Grassi, G., Scuntero, P., Trepiccioni, R., et al. Optimizing insulin injection technique and its effect on blood glucose control. J Clin Translat Endocrinol 1:4 (2014), 145–150.
144. 144 Mujika-Zabaleta, A., Forbes, A., While, A., et al. Relationship between diabetes knowledge, glycaemic control and quality of life: pilot study. Diabetes Primary Care 12 (2010), 376–381.
145. 145 Reach, G., Patient non-adherence and healthcare-provider inertia are clinical myopia. Diabetes Metab 34:4 (2008), 382–385.
146. 146 Genev, N.M., Flack, J.R., Hoskins, P.L., et al. Diabetes education: whose priorities are met?. Diabet Med 9:5 (1992), 475–479.
147. 147 Davidson, M., No need for the needle (at first). Diabetes Care 31:10 (2008), 2070–2071.
148. 148 Klonoff, D.C., The pen is mightier than the needle (and syringe). Diabetes Technol Ther 3:4 (2001), 631–633.
149. 149 Pettis, R.J., Ginsberg, B., Hirsch, L., et al. Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection. Diabetes Technol Ther 13:4 (2011), 435–442.
150. 150 Heinemann, L., Hompesch, M., Kapitza, C., Harvey, N.G., Ginsberg, B.H., Pettis, R.J., Intra-dermal insulin lispro application with a new microneedle delivery system led to a substantially more rapid insulin absorption than subcutaneous injection. Diabetologia, 49, 2006, 755 abstract 1014.
151. 151 MedlinePlus website. https://www.nlm.nih.gov/medlineplus. Accessed July 1, 2016.
152. 152 Nagase, T., Katsura, Y., Iwaki, Y., et al. The insulin ball. Lancet, 373(9658), 2009, 184.
153. 153 Okamura, S., Hayashino, Y., Kore-Eda, S., Tsujii, S., Localized amyloidosis at the site of repeated insulin injection in a patient with type 2 diabetes. Diabetes Care, 36(12), 2013, e200.
154. 154 Nagase, T., Iwaya, K., Iwaki, Y., et al. Insulin-derived amyloidosis and poor glycemic control: a case series. Am J Med 127:5 (2014), 450–454.
155. 155 Swift, B., Hawkins, P.N., Richards, C., Gregory, R., Examination of insulin injection sites: an unexpected finding of localized amyloidosis. Diabet Med 19:10 (2002), 881–882.
156. 156 Blanco, M., Hernández, M.T., Strauss, K.W., Amaya, M., Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab 39:5 (2013), 445–453.
157. 157 Sun, Z., Li, Q., Ji, L., et al. Lipohypertrophy: prevalence, risk factors, clinical characteristics, and economic burden of insulin-requiring patients in China. Diabetologia 58:suppl 1 (2015), S438–S439.
158. 158 Famulla, S., Hövelmann, U., Fischer, A., et al. Insulin injection into lipohypertrophic tissue: blunted and more variable insulin absorption and action, and impaired postprandial glucose control. Diabetes Care, 2016 Jul 13 pii: dc160610.
159. 159 Hovelmann, U., Famulla, S., Hermanski, L., et al. Insulin injection into regions with lipohypertrophy (LHT) worsens postprandial (PP) blood glucose (BG) versus injections into normal adipose tissue (NAT). Diabetes 64:suppl 1 (2015), A254–A255.
160. 160 Ji L, Li Q, Wei G. Lipohypertrophy: prevalence, risk factors and clinical characteristics of insulin-requiring patients in China. Paper presented at: 50th Annual Meeting of the European Association for the Study of Diabetes (EASD); September 15-19, 2014; Vienna, Austria.
161. 161 Conwell, L.S., Pope, E., Artiles, A.M., Mohanta, A., Daneman, A., Daneman, D., Dermatological complications of continuous subcutaneous insulin infusion in children and adolescents. J Pediatr 152:5 (2008), 622–628.
162. 162 Pickup, J., Yemane, N., Brackenridge, A., Pender, S., Nonmetabolic complications of continuous subcutaneous insulin infusion: a patient survey. Diabetes Technol Ther 16:3 (2014), 145–149.
163. 163 Vardar, B., Kizilci, S., Incidence of lipohypertrophy in diabetic patients and a study of influencing factors. Diabetes Res Clin Pract 77:2 (2007), 231–236.
164. 164 Raile, K., Noelle, V., Landgraf, R., Schwarz, H.P., Insulin antibodies are associated with lipoatrophy but also with lipohypertrophy in children and adolescents with type 1 diabetes. Exp Clin Endocrinol Diabetes, 109(8), 2001, 393396.
165. 165 Fujikura, J., Fujimoto, M., Yasue, S., et al. Insulin-induced lipohypertrophy: report of a case with histopathology. Endocr J 52:5 (2005), 623–628.
166. 166 Fernqvist-Forbes, E., Linde, B., Insulin absorption, glucose homeostasis, and lipolysis in IDDM during mental stress. Diabetes Care 14:11 (1991), 1006–1012.
167. 167 Franzen, I., Ludvigsson, J., Specific instructions gave reduction of lipomas and improved metabolic control in diabetic children. Diabetologia, 40(suppl 1), 1997, A615.
168. 168 Li Q, Ji L, Sun Z, et al. Lipohypertrophy (LH) prevalence varies widely between Chinese cities: need for consistent LH diagnostic methods. Paper presented at: 75th Scientific Sessions of the American Diabetes Association; June 5-9, 2015; Boston, MA.
169. 169 Famulla S, Hövelmann U, Fischer A, et al. Lipohypertrophy (LHT) leads to blunted, more variable insulin absorption and action in patients with type 1 diabetes (T1DM). Paper presented at: 75th Scientific Sessions of the American Diabetes Association; June 5-9, 2015; Boston, MA.
170. 170 Hovelmann U, Famulla S, Hermanski L, et al. Insulin injection into regions with lipohypertrophy (LHT) worsens postprandial (PP) blood glucose (BG) versus injections into normal adipose tissue (NAT). Paper presented at: 75th Scientific Sessions of the American Diabetes Association; June 5-9, 2015; Boston, MA.
171. 171 Heinemann, L., Hirsch, L., Hovorka, R., Lipohypertrophy and the artificial pancreas: is this an issue?. J Diabetes Sci Technol 8:5 (2014), 915–917.
172. 172 Del Olmo, M.I., Campos, V., Abellán, P., Merino-Torres, J.F., Piñón, F., A case of lipoatrophy with insulin detemir. Diabetes Res Clin Pract 80:1 (2008), e20–e21.
173. 173 Arranz, A., Andia, V., López-Guzmán, A., A case of lipoatrophy with Lispro insulin without insulin pump therapy. Diabetes Care 27:2 (2004), 625–626.
174. 174 Breznik, V., Kokol, R., Luzar, B., Miljković, J., Insulin-induced localized lipoatrophy. Acta Dermatovenerol Alp Pannonica Adriat 22:4 (2013), 83–85.
175. 175 Swelheim, H.T., Westerlaken, C., van Pinxteren-Nagler, E., Bocca, G., Lipoatrophy in a girl with type 1 diabetes: beneficial effects of treatment with a glucocorticoid added to an insulin analog. Diabetes Care, 35(3), 2012, e22.
176. 176 Babiker, A., Datta, V., Lipoatrophy with insulin analogues in type I diabetes. Arch Dis Child 96:1 (2011), 101–102.
177. 177 Holstein, A., Stege, H., Kovacs, P., Lipoatrophy associated with the use of insulin analogues: a new case associated with the use of insulin glargine and review of the literature. Expert Opin Drug Saf 9:2 (2010), 225–231.
178. 178 Teft, G., Lipohypertrophy: patient awareness and implications for practice. (Clinical Audit). J Diabetes Nurs 6:1 (2002), 20–24.
179. 179 Hambridge, K., The management of lipohypertrophy in diabetes care. Br J Nurs 16:9 (2007), 520–524.
180. 180 Jansà, M., Colungo, C., Vidal, M., Actualización sobre técnicas y sistemas de administración de la insulina (II). Av Diabetol 24:4 (2008), 255–269.
181. 181 Bantle, J.P., Weber, M.S., Rao, S.M., Chattopadhyay, M.K., Robertson, R.P., Rotation of the anatomic regions used for insulin injections and day-to-day variability of plasma glucose in type 1 diabetic subjects. JAMA 263:13 (1990), 1802–1806.
182. 182 Davis, E.D., Chesnaky, P., Site rotation… taking insulin. Diabetes Forecast 45:3 (1992), 54–56.
183. 183 Lumber, T., Tips for site rotation: when it comes to insulin, where you inject is just as important as how much and when. Diabetes Forecast 57:7 (2004), 68–70.
184. 184 Thatcher, G., Insulin injections: the case against random rotation. Am J Nurs 85:6 (1985), 690–692.
185. 185 Nielsen BB, Musaeus L, Gæde P. Attention to injection technique is associated with a lower frequency of lipohypertrophy in insulin treated type 2 diabetic patients. Paper presented at: 34th Annual Meeting of the European Association for the Study of Diabetes (EASD); September 8-12, 1998; Barcelona, Spain.
186. 186 Ampudia-Blasco, J., Girbes, J., Carmena, R., A case of lipoatrophy with insulin glargine. Diabetes Care, 28(12), 2005, 2983.
187. 187 De Villiers, F.P., Lipohypertrophy: a complication of insulin injections. S Afr Med J 95:11 (2005), 858–859.
188. 188 Hauner, H., Stockamp, B., Haastert, B., Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors. Exp Clin Endocrinol Diabetes 104:1 (1996), 106–110.
189. 189 De Coninck, C., Frid, A., Gaspar, R., et al. Results and analysis of the 2008-2009 Insulin Injection Technique Questionnaire survey. J Diabetes 2:3 (2010), 168–179.
190. 190 Hirsch, L., Ji, L., Sun, Z., et al. Lipohypertrophy: prevalence, risk factors and clinical characteristics of insulin-requiring patients in China. Diabetes Technol Ther 17:suppl 1 (2015), A57–A58.
191. 191 Misnikova, I., Dreval, A., Gubkina, V., Rusanova, E., The risk of repeated use of insulin pen needles in patients with diabetes mellitus. J Diabetol 1 (2011), 1–5.
192. 192 Thomas, D.R., Fischer, R.G., Nicholas, W.C., Beghe, C., Hatten, K.W., Thomas, J.N., Disposable insulin syringe reuse and aseptic practices in diabetic patients. J Gen Intern Med 4:2 (1989), 97–100.
193. 193 Puder, J., Atar, M., Muller, B., Pavan, M., Keller, U., Using insulin pen needles up to five times does not affect needle tip shape nor increase pain intensity. Diabetes Res Clin Pract 67:2 (2005), 119–123.
194. 194 Kahara, T., Kawara, S., Shimizu, A., Hisada, A., Noto, Y., Kida, H., Subcutaneous hematoma due to frequent insulin injections in a single site. Intern Med 43:2 (2004), 148–149.
195. 195 Heise, T., Nosek, L., Dellweg, S., et al. Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trial. Diabetes Obes Metab 16:10 (2014), 971–976.
196. 196 Wittmann, A., Köver, J., Kralj, N., et al. Insulin leakage value in relation to pen needle length and administered dose after subcutaneous injection. Diabetes Technol Ther 12:8 (2010), 587–590.
197. 197 Bossi, A.C., Ansah, E.O., Bent needles: another problem in glycaemic control. Diabetes Care, 31(10), 2008, e70.
198. 198 Siegmund, T., Blankenfeld, H., Schumm-Draeger, P.M., Comparison of usability and patient preference for insulin pen needles produced with different production techniques: “thin-wall” needles compared to “regular-wall” needles: an open-label study. Diabetes Technol Ther 11:8 (2009), 523–528.
199. 199 Aronson, R., Gibney, M.A., Oza, K., Bérubé, J., Kassler-Taub, K., Hirsch, L., Insulin pen needles: effects of extra-thin wall needle technology on preference, confidence, and other patient ratings. Clin Ther 35:7 (2013), 923–933.
200. 200 Aronson, R., The role of comfort and discomfort in insulin therapy. Diabetes Technol Ther 14:8 (2012), 741–747.
201. 201 Anderson, G., Meyer, D., Herrman, C.E., et al. Tolerability and safety of novel half milliliter formulation of glatiramer acetate for subcutaneous injection: an open-label, multicenter, randomized comparative study. J Neurol 257:11 (2010), 1917–1923.
202. 202 Brady, K.A., Avner, J.R., Khine, H., Perception and attitude of providers towards pain and anxiety associated with pediatric vaccine injection. Clin Pediatr 50:2 (2011), 140–143.
203. 203 Diamond, S., Matok, I., Pharmacists' anticipated pain compared to experienced pain associated with insulin pen injection and fingertip. Can J Diabetes 35:3 (2011), 282–286.
204. 204 Jorgensen, J.T., Romsing, J., Rasmussen, M., Moller-Sonnergaard, J., Vang, L., Musaeus, L., Pain assessment of subcutaneous injections. Ann Pharmacother 30:7-8 (1996), 729–732.
205. 205 Egekvist, H., Bjerring, P., Arendt-Nielson, L., Pain and mechanical injury to human skin following needle insertions. Eur J Pain 3:1 (1999), 41–49.
206. 206 Arendt-Nielsen, L., Egekvist, H., Bjerring, P., Pain following controlled cutaneous insertion of needles with different diameters. Somatosens Mot Res 23:1-2 (2006), 37–43.
207. 207 Hirsch, L., Gibney, M., Berube, J., Manocchio, J., The impact of a modified needle tip geometry on penetration force as well as acceptability, preference and perceived pain in subjects with diabetes. J Diabetes Sci Technol 6:2 (2012), 328–335.
208. 208 Rubin, R.R., Peyrot, M., Kruger, D.F., Travis, L.B., Barriers to insulin injection therapy: patient and health care provider perspectives. Diabetes Educ 35:6 (2009), 1014–1022.
209. 209 Lee, D.M., How painful is intensive insulin therapy?. [in German] Z Gesamte Inn Med 47:6 (1992), 266–269.
210. 210 Rubino, A., McQuay, L.J., Gough, S.C., et al. Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with type 2 diabetes: a population-based analysis in the UK. Diabet Med 24:12 (2007), 1412–1418.
211. 211 Karter, A.J., Subramanian, U., Saha, C., et al. Barriers to insulin initiation: the translating research into action for diabetes insulin starts project. Diabetes Care 33:4 (2010), 733–735.
212. 212 Fu, A., Qiu, Y., Radican, L., Impact of fear of insulin or fear of injection on treatment outcomes of patients with diabetes. Curr Med Res Opin 25:6 (2009), 1413–1420.
213. 213 Goebel-Fabbri, A.E., Fikkan, J., Franko, D.L., et al. Insulin restriction and associated morbidity and mortality in women with type 1 diabetes. Diabetes Care 31:3 (2008), 415–419.
214. 214 Bienvenu, O.J., Eaton, W.W., The epidemiology of blood-injection: injury phobia. Psychol Med 28:5 (1998), 1129–1136.
215. 215 Larkin, M.E., Capasso, V.A., Chen, C., et al. Measuring psychological insulin resistance: barriers to insulin use. Diabetes Educ 34:3 (2008), 511–517.
216. 216 Zambanini, A., Newson, R.B., Maisey, M., et al. Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract 46:3 (1999), 239–246.
217. 217 Mollema, E.D., Snoek, F.J., Heine, R.J., Assessment of perceived barriers in self-care of insulin-requiring diabetic patients. Patient Educ Couns 29:3 (1996), 277–281.
218. 218 Mollema, E.D., Snoek, F.J., Ader, H.J., et al. Insulin-treated diabetes patients with fear of self-injecting or fear of self-testing: psychological comorbidity and general well-being. J Psychosom Res 51:5 (2001), 665–672.
219. 219 Jenkins, N., Hallowell, N., Farmer, A.J., Holman, R.R., Lawton, J., Initiating insulin as part of the Treating To Target in Type 2 Diabetes (4-T) trial: an interview study of patients' and health professionals' experiences. Diabetes Care 33:10 (2010), 2178–2180.
220. 220 Cocoman, A., Barron, C., Administering subcutaneous injections to children: what does the evidence say?. J Child Young People Nurs 2:2 (2008), 84–89.
221. 221 Karlegärd, M., Eldholm, S., Lindblad, B., Sigström, L., Stickrädsla hos barn och ungdomar med diabetes (Fear of injection in children and adolescents with diabetes). Sv Läkaresällskapets Handlingar Hygiea, 110, 2001, 301(32P).
222. 222 Polonsky, W.H., Jackson, R., What's so tough about taking insulin? addressing the problem of psychological insulin resistance in type 2 diabetes. Clin Diabetes 22:3 (2004), 147–150.
223. 223 Polonsky, W.H., Fisher, L., Guzman, S., Villa-Caballero, L., Edelman, S.V., Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 28:10 (2005), 2543–2545.
224. 224 Meece, J., Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educ 32:suppl 1 (2006), 9S–18S.
225. 225 Davis, S.N., Renda, S.M., Psychological insulin resistance: overcoming barriers to starting insulin therapy. Diabetes Educ 32:suppl 1 (2006), 146S–152S.
226. 226 Pergallo-Dittko, V., Rethinking subcutaneous injection technique. Am J Nurs 97:5 (1997), 71–72.
227. 227 Hanas, R., Ludvigsson, J., Experience of pain from insulin injections and needle phobia in young patients with IDDM. Pract Diabetes Int 14:4 (1997), 95–99.
228. 228 Hanas, S.R., Carlsson, S., Frid, A., Ludvigsson, J., Unchanged insulin absorption after 4 days' use of subcutaneous indwelling catheters for insulin injections. Diabetes Care 20:4 (1997), 487–490.
229. 229 Hanas, R., Adolfsson, P., Elfvin-Akesson, K., et al. Indwelling catheters used from the onset of diabetes decrease injection pain and pre-injection anxiety. J Pediatr 140:3 (2002), 315–320.
230. 230 Burdick, P., Cooper, S., Horner, B., Cobry, E., McFann, K., Chase, H.P., Use of a subcutaneous injection port to improve glycemic control in children with type 1 diabetes. Pediatr Diabetes 10:2 (2009), 116–119.
231. 231 Sonoki, K., Yoshinari, M., Iwase, M., et al. Regurgitation of blood into insulin cartridges in the pen-like injectors. Diabetes Care 24:3 (2001), 603–604.
232. 232 Shikata, T., Karasawa, T., Abe, K., et al. Hepatitis B e antigen and infectivity of hepatitis B virus. J Infect Dis 136:4 (1977), 571–576.
233. 233 Scioli, D., Pizzella, T., Vollaro, L., Nardiello, S., De Feo, L., The action of VIRKON No Foam on the hepatitis B virus. Eur J Epidemiol 13:8 (1997), 879–883.
234. 234 Herdman, M., Larck, C., Hoppe Schliesser, S., Jelic, T., Biological contamination of insulin pens in a hospital setting. Am J Health Syst Pharm 70:14 (2013), 1244–1248.
235. 235 Pickup, J.C., Keen, H., Parsons, J.A., Alberti, K.G., Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. Br Med J 1:6107 (1978), 204–207.
236. 236 Heinemann, L., Krinelke, L., Insulin infusion set: the Achilles heel of continuous subcutaneous insulin infusion. J Diabetes Sci Technol 6:4 (2012), 954–964.
237. 237 McVey, E., Keith, S., Herr, J.K., Sutter, D., Pettis, R.J., Evaluation of intradermal and subcutaneous infusion set performance under 24-hour basal and bolus conditions. J Diabetes Sci Technol 9:6 (2015), 1282–1291.
238. 238 Gibney, M., Xue, Z., Swinney, M., Bialonczyk, D., Hirsch, L., Reduced silent occlusions with a novel catheter infusion set (BD FlowSmart): results from two open-label comparative studies. Diabetes Technol Ther 18:3 (2016), 136–143.
239. 239 Schmid, V., Hohberg, C., Borchert, M., Forst, T., Pfützner, A., Pilot study for assessment of optimal frequency for changing catheters in insulin pump therapy: trouble starts on day 3. J Diabetes Sci Technol 4:4 (2010), 976–982.
240. 240 Bolick, N., Performance qualification of a novel subcutaneous insulin infusion set using medical imaging. Diabetes, 64(suppl 1), 2015, A278.
241. 241 Renard, E., Guerci, B., Leguerrier, A.M., Boizel, R., Accu-Chek FlexLink Study Group. Lower rate of initial failures and reduced occurrence of adverse events with a new catheter model for continuous subcutaneous insulin infusion: prospective, two-period, observational, multicenter study. Diabetes Technol Ther 12:10 (2010), 769–773.
242. 242 van Bon, A.C., Bode, B.W., Sert-Langeron, C., DeVries, J.H., Charpentier, G., Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial. Diabetes Technol Ther 13:6 (2011), 607–614.
243. 243 Patel, P.J., Benasi, K., Ferrari, G., et al. Randomized trial of infusion set function: steel versus teflon. Diabetes Technol Ther 16:1 (2014), 15–19.
244. 244 Thethi, T.K., Rao, A., Kawji, H., et al. Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion. J Diabetes Complications 24:2 (2010), 73–78.
245. 245 American Association of Diabetes Educators. Insulin Pump Therapy: Best Practices in Choosing and Using Infusion Devices. 2011, American Association of Diabetes Educators, Chicago, IL.
246. 246 Strauss, K., WISE Consensus Group. WISE recommendations to ensure the safety of injections in diabetes. Diabetes Metab 38:suppl 1 (2012), S2–S8.
247. 247 Kiss, P., de Meester, M., Braeckman, L., Needlestick injuries in nursing homes: the prominent role of insulin pens. Infect Control Hosp Epidemiol 29:12 (2008), 1192–1194.
248. 248 Demir, M., Serin, E., Göktürk, S., Ozturk, N.A., Kulaksizoglu, S., Ylmaz, U., The prevalence of occult hepatitis B virus infection in type 2 diabetes mellitus patients. Eur J Gastroenterol Hepatol 20:7 (2008), 668–673.
249. 249 Vaccines and immunizations. Centers for Disease Control and Prevention website. http://www.cdc.gov/vaccines. Accessed June 9, 2016.
250. 250 Simó, R., Hernández, C., Genescà, J., Jardí, R., Mesa, J., High prevalence of hepatitis C virus infection in diabetic patients. Diabetes Care 19:9 (1996), 998–1000.
251. 251 Mondy, K., Overton, E.T., Grubb, J., et al. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis 44:5 (2007), 726–734.
252. 252 Lee, J.M., Botteman, M.F., Nicklasson, L., Cobden, D., Pashos, C.L., Needlestick injury in acute care nurses caring for patients with diabetes mellitus: a retrospective study. Curr Med Res Opin 21:5 (2005), 741–747.
253. 253 De Schryver, A., Claesen, B., Meheus, A., van Sprundel, M., François, G., European survey of hepatitis B vaccination policies for healthcare workers. Eur J Public Health 21:3 (2011), 338–343.
254. 254 Paton, N., Why we must stop needlestick injuries. Nurs Times 102:40 (2006), 16–18.
255. 255 Melissa, K., Schaefer MK, Kossover RA, Perz JF. Sharing insulin pens: are you putting patients at risk?. Diabetes Care 36:11 (2013), e188–e189.
256. 256 Occupational Safety and Health Administration. Occupational exposure to bloodborne pathogens: needlesticks and other sharps injuries: finale rule. Fed Regist 66:12 (2001), 5317–5325.
257. 257 Pugliese, G., Germanson, T.P., Bartley, J., et al. Evaluating sharps safety devices: meeting OSHA's intent. Infect Control Hosp Epidemiol 22:7 (2001), 456–458.
258. 258 Council Directive 2010/32/EU. Official Journal of the European Union website. http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ: L:2010:134:0066:0072:EN: PDF. Accessed June 9, 2016.
259. 259 EU Commission for Employment, Social Affairs, and Inclusion. New legislation to reduce injuries for 3.5 million healthcare workers in Europe. http://europa.eu/rapid/press-release_IP-10-243_en.htm?locale=en. Published March 8, 2010. Accessed July 1, 2016.
260. 260 Article 3.2 says that where risk cannot be eliminated the employer shall take appropriate measures to minimise the risks. Appropriate measures to minimise the risks would include the provision by employers of safer needle devices. (Cf. NHS Employers, Implementation advice on sharps agreement, 12th October 2010). http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32010L0032&from=EN. Accessed August 4, 2016.
261. 261 The Directive specifically requires: ‘eliminating the unnecessary use of sharps by implementing changes in practice and on the basis of the results of the risk assessment, providing medical devices incorporating safety-engineered protection mechanisms.’ Council Directive 2010/32/EU, Official Journal of the European Union, L134/71 and L134/69. http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32010L0032&from=EN. Accessed August 4, 2016.
262. 262 NACO (National AIDS Control Organisation) guidelines from India. National AIDS Control Organisation website. http://www.naco.gov.in/NACO. Accessed June 8, 2016.
263. 263 World Health Organization. WHO Guideline on the Use of Safety-Engineered Syringes for Intramuscular, Intradermal and Subcutaneous Injections in Health-care Settings. 2015, World Health Organization, Geneva, Switzerland.
264. 264 Kalra, S., Girdhar, R., Sahay, R., Green diabetology. Indian J Endocrinol Metab 19:6 (2015), 698–700.
265. 265 Adams, D., Elliott, T.S.J., Impact of safety needle devices on occupationally acquired needle stick injuries: a four-year prospective study. J Hosp Infect 64:1 (2006), 50–55.
266. 266 Tarantola, A., Golliot, F., Astagneau, P., Fleury, L., Brucker, G., Bouvet, E., CCLIN Paris-Nord blood and body fluids (BBF) exposure surveillance taskforce: four-year surveillance from the northern France network. Am J Infect Control 31:6 (2003), 357–363.
267. 267 Cullen, B.L., Genasi, F., Symington, I., et al. Potential for reported needle stick injury prevention among healthcare workers in NHS Scotland through safety device usage and improvement of guideline adherence: an expert panel assessment. J Hosp Infect 63:4 (2006), 445–451.
268. 268 Mendelson MH, Lin-Chen BY, Finkelstein-Blond L, Bailey E, Kogan G. Evaluation of a safety IV catheter (IVC) (Becton Dickinson, INSYTE™ AUTOGUARD™): final report. Paper presented at: Eleventh Annual Scientific Meeting of the Society for Healthcare Epidemiology of America (SHEA); April 1-3, 2001; Toronto, Ontario, Canada.
269. 269 Louis, N., Vela, G., Groupe Projet. Évaluation de l'efficacité d'une mesure de prévention des accidents d'exposition au sang au cours du prèlévement de sang veineux. Bulletin Épidémiologique Hebdomadaire 51 (2002), 260–261.
270. 270 Jagger, J., Perry, J., Gomaa, A., Phillips, E.K., The impact of U.S. policies to protect healthcare workers from bloodborne pathogens: the critical role of safety-engineered devices. J Infect Public Health 1:2 (2008), 62–71.
271. 271 Bossi, A.C., Veronesi, G., Poerio, C.S., et al. A prospective study for introducing insulin pens and safety needles in a hospital setting: the SANITHY (SAfety Needles and Insulin pens in Treviglio Hospital-ItalY) Study. Curr Diabetes Rev 12 (2016), 1–8.
272. 272 Veronesi, G., Poerio, C.S., Braus, A., et al. Insulin therapy in hospitalized patients with diabetes: determinants of nurse satisfaction using pen devices: the SANITHY (SAfety Needles and Insulin pens at Treviglio Hospital – ItalY) Study. Clin Diabetes Endocrinol 15 (2015), 1–15.
273. 273 Adams, D., Safety-engineered needle devices: evaluation prior to introduction is essential. J Hosp Med 79:2 (2011), 174–175.
274. 274 Adams, D., Elliott, T.S.J., A comparative user evaluation of three needle protective devices. Br J Nurs 12:8 (2003), 470–474.
275. 275 Vos, D., Gotz, H.M., Richardus, J.H., Needlestick injury and accidental exposure to blood: the need for improving the hepatitis B vaccination grade among health care workers outside the hospital. Am J Infect Control 34:9 (2006), 610–612.
276. 276 Workman, R.G.N., Safe injection techniques. Primary Health Care 10 (2000), 43–50.
277. 277 Bain, A., Graham, A., How do patients dispose of syringes?. Pract Diabetes Int 15:1 (1998), 19–21.
278. 278 FIT website. http://www.fit4diabetes.com. Accessed June 9, 2016.
279. 279 FIT-PHIL: Forum for Injection Technique Philippines. 2014 Taguig City, Philippines: BD.
280. 280 The Turkish guidelines edited by Prof. Dr. Ahmet Kaya. BD website. http://www.bd.com/contentmanager/b_article.asp?Item_ID=27814&ContentType_ID=2&BusinessCode=20306&d=&s=tr&dTitle=Turkey&dc=tr&dcTitle=Turkey. Accessed June 9, 2016.
281. 281 Belgian guidelines in French: Nouvelles recommandations concernant les injections chez les personnes atteintes de diabète. BD Belgium website. http://www.bddiabetes.be. Accessed June 9, 2016.
282. 282 Belgian guidelines in Flemish: Nieuwe aanbevelingen voor injecties bij mensen met diabetes. BD Belgium website. http://www.bddiabetes.be. Accessed June 9, 2016.
283. 283 Italian guidelines edited by Prof. Sandro Gentile: consensus AMD-OSDI sulle Tecniche iniettive nel soggetto diabetic. A cura del Gruppo Inter-Societario AMD-OSDI sulle Tecniche iniettive. Il Giornale di AMD 2014;17:176-181. http://www.giornalediamd.it/pdf/2014_3_F/8.pdf. Accessed June 9, 2016.
284. 284 Guidelines for correct injection technique and for prevention of lipodystrophy and the risk of accidental punctures. AMD-OSDI-SID Worksheet. Gentile S, Giancaterini A, Cucco L, Lograsso G, Porcellati F, Laviola L. Il Giornale di AMD 2015;18:209-217. http://www.aemmedi.it/files/Linee-guida_Raccomandazioni/2015/Documento_di_consenso_2015.pdf. Accessed June 9, 2016.
285. 285 Chinese guidelines published in 2011 in collaboration with the China Diabetes Society. China Diabetes Society website. http://www.diab.net.cn/guideline.jsp. Accessed June 9, 2016.